GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Seems the GlaxoSmithKline business development groups has been very busy lately. Earlier today I posted about GSK acquiring Praecis and before that they acquired Domantis. Now they are concentrating on deals and have entered into a large one with Genmab.
PharmaLive: GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
GSK sign world’s-biggest licensing deal with Genmab:
This deal is worth $2.7 billion making it the largest deal that I know of (the Erbitux deal between Bristol-Myers Squibb and Imclone was $2 billion).
HuMax-CD20 (ofatumumab) is a human monoclonal antibody in phase III clinical trials for treatment of CD20 positive B-cell chronic lymphocytic leukemia and follicular non-Hodgkin’s lymphoma. Is it also being investigated in phase II trials for rheumatoid arthritis. Analysts (whose numbers I take with a block of salt) say the market for it could be $2-5 billion! GSK hopes to be able to fill an NDA for the compound sometime in 2008.
Technorati Tags: Genmab, GlaxoSmithKline, HuMax-CD20, pharmaceutical deals, ofatumumab
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
